abstract |
A synergistic pharmaceutical combination or composition is disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a histamine H2 receptor blocking agent, which increases intragastric pH, and an acid degradable antibacterial compound. In particular, the combination is directed to the treatment of infections by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds. |